Clinical Trial

Percutaneous Coronary Intervention for Myocardial Infarction at Fujian Provincial Hospital

Study acronym: Fu-AMI
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Research Objectives: This clinical trial aims to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) in patients with myocardial infarction (MI). The primary objective is to determine whether this approach can reduce the incidence of major adverse cardiovascular events (MACE) compared to current conservative treatment. Research Questions: This study aims to address the following key questions: Does standard PCI improve the clinical outcomes of MI patients (such as cardiovascular death, recurrent myocardial infarction, or revascularization due to ischemia-driven vascular reconstruction)? How safe is PCI, especially in terms of bleeding risk, surgical-related complications, or other adverse events? Does PCI have a significant impact on specific secondary endpoints (such as stent thrombosis, hospitalization for heart failure, or quality of life indicators)?
Trial Details
NCT Number NCT07405788
Lead Sponsor Kaiyang Lin
Conditions Myocardial Infarction
Enrollment 1,344 participants
Start Date 2017-01-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-12